ClinicalTrials.gg

Program

ibramvibart

Also written as “VYD2311”, “VYD2311-SD” and “VYD2311-MD”.

Its studies are mostly in COVID-19 · Post-Acute COVID-19 Syndrome, led by Invivyd.

Furthest: phase 3, since Dec 18, 20254 company-led studies, 3 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Invivyd43 open or runningphase 3since Dec 18, 2025Jul 18, 2024Jun 2027phase 2 · NCT07899346

Also a collaborator on its studies: novotech-australia-pty-limited.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 18, 2024First study: phase 1 study in COVID-19First studyNCT06523153 · 40 enrolled · Australia
  2. Dec 18, 2025Phase 3 study in COVID-19Phase 3 reachedNCT07298434 · 1,770 enrolled · United States
  3. Jun 8, 2026Phase 3 study in COVID-19NCT07655180 · 210 enrolled · United States
  4. Oct 20, 2026Phase 2 study in Post-Acute COVID-19 SyndromeNCT07899346 · 130 planned

Ahead

  1. Jun 2027Primary completion: phase 2 study in Post-Acute COVID-19 SyndromeNCT07899346

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07899346Post-Acute COVID-19 Syndrome2Not yet recruitingJun 2027130
NCT07655180COVID-19 · United States3CompletedAug 15, 2026210
NCT07298434COVID-19 · United States3Active, not recruitingAug 20261,770
NCT06523153COVID-19 · Australia1Active, not recruitingMay 202540

How it is read

Names in the registry

  • “VYD2311”, 3 entries
  • “VYD2311-SD”, 1 entry
  • “VYD2311-MD”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.